Biological Psychiatry. Editor: J. Mendlewicz (Brussels). Original Paper
Association between Norepinephrine Transporter Gene Polymorphism and Major DepressionRyu S.-H.a · Lee S.-H.b · Lee H.-J.c · Cha J.-H.c · Ham B.-J.c · Han C.-S.c · Choi M.-J.c · Lee M.-S.c
aDepartment of Psychiatry, Konkuk University College of Medicine, bDepartment of Psychiatry, Inje University College of Medicine, and cDepartment of Psychiatry, Korea University College of Medicine, Seoul, Korea
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Noradrenergic and serotonergic abnormalities have long been implicated in patients with major depression. The novel selective norepinephrine reuptake inhibitor reboxetine has been shown to be at least as effective as imipramine, desipramine and fluoxetine in the treatment of major depression. It is suggested that the dysfunction of the norepinephrine transporter (NET) may be related to major depression. Although the transcriptional activity related to the NET gene expression is little known, it may be a good candidate gene for major depression. Therefore, we investigated whether the T-182C polymorphism of the NET gene is associated with major depression in a Korean sample of 112 major depression patients compared with 136 healthy controls. We found a significantly lower frequency in TT genotype in patients with major depression than in normal controls when the genotypes of T-182C polymorphism were classified into two groups: TT group versus TC + CC group (p = 0.019). This result suggests that the T-182C polymorphism in the NET gene might be associated with major depression.
© 2004 S. Karger AG, Basel
- Lake CR, Pickar D, Ziegler MG, Lipper S, Slater S, Murphy DL: High plasma norepinephrine levels in patients with major affective disorder. Am J Psychiatry 1982;139:1315–1318.
- Roy A, Pickar D, Dejong J, Karoum F, Linnoila M: Norepinephrine and its metabolites in cerebrospinal fluid, plasma and urine: Relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry 1988;45:849–857.
- Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, Murburg HM, Ashleigh EA, Castillo S, Peskind ER, Pascualy M, Halter JB: Sympathetic nervous system activity in major depression. Arch Gen Psychiatry 1994;51:411–422.
- DeBellis M, Geracioti T, Altemus M: Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biol Psychiatry 1993;33:636–641.
- Owens MJ: Molecular and cellular mechanisms of antidepressant drugs. Depress Anxiety 1997;4:153–159.
- Bönisch H, Brüss M: The noradrenaline transporter of the neuronal plasma membrane. Ann NY Acad Sci 1994;733:193–202.
- Amara SG, Kuhar MJ: Neurotransmitter transporters: Recent progress. Annu Rev Neurosci 1993;16:73–93.
- Szot P, Ashliegh EA, Kohen R, Petrie E, Dorsa DM, Veith R: Norepinephrine transporter mRNA is elevated in the locus coeruleus following short- and long-term desipramine treatment. Brain Res 1993;618:308–312.
Massana J: Reboxetine versus fluoxetine: An overview of efficacy and tolerability. J Clin Psychiatry 1998;59(suppl 14):8–10.
- Scates AC, Doraiswamy PM: Reboxetine: A selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 2000;34:1302–1312.
- Klimeck V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G, Ordway GA: Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997;17:8451–8458.
- Porzgen P, Bonisch H, Bruss M: Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem Biophys Res Commun 1995;215:1145–1150.
- Zill P, Engel R, Baghai TC, Juckel G, Frodl T, Müller-Siecheneder F, Zwanzger P, Schüle C, Minov C, Behrens S, Rupprecht R, Hegerl U, Möller HJ, Bondy B: Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression. Neuropsychopharmacology 2002;26:489–493.
- Kim CH, Kim HS, Cubells JF, Kim KS: A previously undescribed intron and extensive 5′ upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J Biol Chem 1999;274:6507–6518.
- Stöber G, Nothen MM, Porzgen P, Bruss M, Bonisch H, Knapp M, Beckmann H, Propping P: Systematic search for variation in the human norepinephrine transporter gene: Identification of five naturally occurring missense mutations and study of association with major psychiatric disorders. Am J Med Genet 1996;67:523–532.
- Hadley D, Hoff M, Holik J, Reimherr F, Wender P, Coon H, Byerley W: Manic-depression and the norepinephrine transporter gene. Hum Hered 1995;45:165–168.
- Owen D, Du L, Bakish D, Lapierre YD, Hrdina PD: Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res 1999;87:1–5.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.